We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




T-Cells with CD20 Protein Marker May Drive Early Multiple Sclerosis

By LabMedica International staff writers
Posted on 03 Nov 2021
Multiple sclerosis (MS) is a condition that can affect the brain and spinal cord, causing a wide range of potential symptoms, including problems with vision, arm or leg movement, sensation or balance. More...
It's a lifelong condition that can sometimes cause serious disability, although it can occasionally be mild.

While the cause of MS is unclear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors, such as viral infections. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.

A team of scientists led by the University of Pennsylvania (Philadelphia, PA, USA) conducted detailed analyses of the immune cells found in the blood of MS patients before and after starting on ocrelizumab for the first time. The cells of two patient groups were analyzed: a set of 23 individuals with either relapsing-remitting (RRMS) or primary progressive disease PPMS who had not received prior therapy, and another group of 35 patients with RRMS. Phenotypic and functional immune profiles were comprehensively assessed by multi-parametric flow cytometry in high-quality cryopreserved peripheral blood mononuclear cells (PBMC).

The investigators reported that the results from both sets of patients were generally similar, with the anti-CD20 therapy leading to a sharp decrease in numbers of B-cells, as expected. The treatment also had marked effects on T-cells, of which there are two main types. One, known as CD8+ T-cells, is a type of cell that is able to kill other cells, for example, cancer cells or cells infected with a virus. By contrast, CD4+ T-cells, the other type, mainly act by helping to coordinate the activity of other components of the immune system, including B-cells. By analyzing specific markers on and in the cells, the team deduced that both the CD4+ and the CD8+ T-cells removed by anti-CD20 therapies were generally pro-inflammatory.

Furthermore, the removed cells showed evidence of being able to get into the central nervous system or CNS, comprised of the brain and spinal cord. The body has several systems in place that normally tightly control which immune cells are able to get into the CNS. Additional analyses showed that most CD8+ T-cells that were removed by ocrelizumab treatment expressed CD20; in other words, it’s likely that the treatment was directly killing these cells. By contrast, CD4+ depletion was not fully explained by the direct effects of targeting CD20.

The authors concluded that their study provided novel insights into both the mode of action of anti-CD20 and mechanisms underlying MS relapse biology. They distinguished the impact of anti-CD20 on CD8+ T cells (largely direct removal of CD20-expressing cells), versus the impact of anti-CD20 on CD4+ T cells (a combination of direct removal, and indirect effects, presumably through depletion of B cells resulting in their diminished in vivo interactions with the CD4+ T cells). The strong inverse correlation with disease activity suggests that CD20-expressing CD8+ T cells leaving the circulation (possibly to the CNS) participate in early encephalitogenic events involved in MS relapse development. The study was presented at the Virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis held October 13-15, 2021 (ECTRIMS).

Related Links:
University of Pennsylvania


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.